parkinson disease

Question 1

What is parkinson disease?

Answer 1

Neurodegenerative, progressive disease
primarily involving the dopamine generating neurones in the substantia nigra

Question 2

Parkinson disease is characterised by?

Answer 2

1) bradykinesia,
2) rigidity,
3) tremor, and
4) postural instability

Question 3

First described by ———————
Identified its major symptoms and called it ————–
Research progressed slowly until the ———-
60’s linked the disease to the loss of cells that produce —————-
Development of DA replacement therapies which still remain the mainstay of treatment to this day

Answer 3

British doctor James Parkinson
“the shaking palsy”
1960’s
dopamine (DA)

Question 4

PD occurs in about ————— and in about ——————

There are also familial cases of early onset PD from age ——————–

There is also a rarer form of juvenile onset PD from age ———–

Answer 4

1% of the population aged 60 years
4% at 80 years.

(age range 21–40 years)
(younger than 21 years of age)

Question 5

Parkinsonism presents the same kind of clinical symptoms with Parkinson disease. TRUE or FALSE

Answer 5

true

Question 6

What are the symptoms of parkinsonism

Answer 6

Tremor
bradykinesia
rigidity

Question 7

what causes the Parkinsonism

Answer 7

DRUGS – Anti psychotics, metaclopramide, TCA, MPTP
Vascular disease
Parkinson plus syndromes (multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration, Lewy-body dementia)
Trauma

Question 8

What is the difference between Parkinson clinical symptoms and that of Parkinsonism

Answer 8

Parkinsonism symptoms are reversible

Question 9

what are the classic TRIAD core diagnostic symptoms of PD

Answer 9

BRADYKINESIA / slowness
RIGIDITY / stiffness / increased tone
TREMOR / pill rolling / 4-6 Hz /resting
AND
Postural instability

Question 10

what are the initial symptoms of PD

Answer 10

First signs can be mistaken for another condition.
Can be considered by the patient as a normal part of the aging process.
Persistent mild fatigue
Handwriting might become “shaky”
Person might feel unbalanced or have difficulty performing sit-to-stands
Agitation, irritability, & depression
Lack of affect (masked face phenom)
Initial symptoms can go on for years

Question 11

what are the motor symptoms of PD

Answer 11

Hand tremors - rhythmic back-and-forth motion of the thumb.
Rigidity or resistance to movement
Muscles associated with movement all have opposing muscles - when one is activated, the other is relaxed.
In PD - both sets of muscles remain engaged and contracted - rigidity
Spontaneous movements can become progressively slower and may actually cease - bradykinesia
Impaired balance and coordination - postural instability
- Patients lean unnaturally backward or forward, head down and stooped stance
-Become vulnerable to falls

Question 12

Physical presentation of PD

Answer 12

Rigidity and trembling of head
Rigidity and trembling of extremities
forward tilt of trunk
Reduced arm swinging
shuffling gait with short steps

Question 13

List the non motor symptoms

Answer 13

Depression
Emotional Changes (Irritable, pessimistic, fearful, become dependent or isolated)
Memory Loss (slower thought processes)  Dementia with Lewy Bodies (DLB)
Swallowing Difficulties
Speech Problems
Bladder/Bowel disorders
Excessive sweating
Sleep Disturbance

Question 14

what could be causing difficulty in movement in PD, Limb can not be kept still

Answer 14

Degeneration of pigmented neurones in the pars compacta of the substantia nigra.
Lewy Bodies
Degeneration of brainstem nuclei

Question 15

What are Lewy bodies

Answer 15

They are prominent, composed of insoluble composed of aggregates containing a protein called alpha-synuclein (AS)

Question 16

Explain Alpha synuclein protein

Answer 16

it is indispensable for life, it is found in nucleus but primarily at the presynaptic terminal

controls neurotransmitters release

Question 17

The level of expression of alpha synuclein determines whether it can aggregate and form lewy bodies. TRUE or FALSE

Answer 17

TRUE

Question 18

Explain why expression level of alpha synuclein is important

Answer 18

Expression level of AS very important > increased AS expression > AS aggregation > LBs > death of SN neurons > mutations that lead to increased AS expression > vulnerability to developing PD.

Question 19

In normal aging, explain AS expression

Answer 19

Normal aging > increased AS expression > inherent vulnerability to develop PD

Question 20

REFER TO SLIDE 13-16 ON THE PP

Question 21

explain the neurobiological motor symptoms of PD

Answer 21

The Basal Ganglia
SN neurons produce/release dopamine
Main targets are caudate nucleus and putamen (striatum)
This basal ganglia pathway is involved in regulation of movement (Extrapyramidal Motor System)
Cells of substantia nigra degenerate
Neurons of striatum are no longer well regulated
Results in loss of control of movements – leads to symptoms characteristic of Parkinson’s disease

Question 22

Explain the neurological non motor symptoms of PD

Answer 22

Apart from DA neurons degenerating, cell death is found in the following brain regions as well:

1.Locus coeruleus degeneration (NA)
Emotional changes
Anxiety
Stress
2. Nucleus Basalis of Meyenert degeneration (Ach)
Memory
Cognition
3. Enteric nervous system neurotransmitter release (GIT)
constipation; swallowing; drooling

Question 23

what causes Parkinson disease

Answer 23

Majority of cases are of no known cause > Idiopathic PD.
Genetics (alpha synuclein e.g)
Environmental factors (toxins e.g. MPTP)
Oxidative Stress > impairment in energy regulation > cell death

Question 24

What are the pharmacotherapy strategies for motor symptoms of PD

Answer 24

Dopamine replacement
1.DA receptor activation  dopamine receptor agonists
2.Preventing DA breakdown (Mono amine oxidase 3.inhibitors and Catechol-O-Methyl Transferase Inhibitors)
4.Antimuscarinic drugs

Question 25

REFER TO SLIDE 21

Question 26

Dopamine replacement

Answer 26

Mainstay of PD first line therapy Cannot administer DA itself as it does not cross the blood brain barrier (BBB). Use levodopa (L-DOPA) > precursor amino acid converted to DA > L-Dopa can cross the BBB and is coveted to DA in the brain. L-dopa susceptible to degradation by enzyme dopa decarboxylase which is also present in the periphery > potential decrease amounts getting into brain > administer a preparation that contains L-dopa AND a peripheral dopa decarboxylase inhibitor > Benzerazide (CO-BENELDOPA) > Carbidopa (CO-CARELDOPA) effectively extending the duration of drug action and ensuring that lower doses of L-DOPA can be used  minimising peripheral side effects.

Question 27

explain L-DOPA treatment

Answer 27

Initiated in lowest dose and increased in small increment > minimise off-target effects. Final dose as low as possible. Choose most effective dosing intervals to avoid motor fluctuations Effective in treating bradykinesia and rigidity Less effective in reducing tremor Often ineffective in relieving problems related to balance

Question 28

explain long term L-dopa effectiveness in PD

Answer 28

Initially effective but diminishes with time Although no change in progression, its early use diminishes mortality Motor fluctuations > after 4 – 6 and most patients within 10 years >Fluctuations relate to timing of L-dopa intake >Termed ON/OFF phenomenon ON > marked improvement in mobility OFF > marked akinesia

Question 29

what are the side effects of L-DOPA. Early SE

Answer 29

Gastrointestinal Side Effects Cardiovascular Side Effects. Orthostatic or Postural Hypotension. Behavioural Side Effects. Abnormal Involuntary Movements (Dyskinesia) On-Off symptoms

Question 30

What are the Dopamine receptor modulators and how do they work

Answer 30

1. Amantadine (no longer used nowadays) Antiviral agent found to have anti-parkinsonian activity acts by releasing dopamine from intact dopamine terminals in the striatum. 2. Dopaminergic agonists (first line treatment) Potentially useful as a first-line treatment option for early PD because they delay the onset of motor fluctuations and dyskinesia. Act directly on selected DA receptors Have longer half-lives than L-DOPA  reduce peaks and troughs  prevent the motor complications in early-stage PD or even reverse motor complications initiated in late-stage PD. Also allows for concomitant therapy with lower dose of L-dopa in unresponsive patients Cause fewer motor side effects than L-dopa Associated with more psychiatric side effects (impulse control; pathological gambling  stimulation of DA receptors in reward pathways)

Question 31

What are the dopamine receptor agonists and explain each of them

Answer 31

1.Bromocriptine Agonist at D2 receptors Widely used to PD and endocrine disorders 2. Pergolide Agonist at D1 & D2 receptors Widely used and potentially more effective than Bromocriptine (increases ON time) allowing decrease in L-dopa dose Associated with valvular heart disease, so use waning in favour of newer agents 3.Pramipexole Agonist at D3 receptors Effective as monotherapy in mild PD Effective as co-therapy with L-dopa in advanced PD May lessen affective symptoms of PD Potentially neuroprotective effect 4.Ropinirole Selective agonist at D2 receptors Effective as monotherapy in mild PD Effective “smoothening” the response to L-dopa 5. Apomorphine Potent DA receptor agonist administered s.c under specialist conditions Helpful in advanced cases unresponsive to other therapies to refractory motor fluctuations

Question 32

REFER TO SLIDE 29

Question 33

List the two types of MAOIs in the brain

Answer 33

1) MAO-A (metabolises NA & 5HT); 2) MAO B (metabolises DA) > inhibit MAO-B > less DA broken down > increase amount of DA in the brain

Question 34

list and explain MAOIs drugs

Answer 34

1.Selegiline Irreversible inhibitor of MAO-B >prevents DA breakdown > prolongs antiparkinsonian effect of L-dopa > lower L-dopa dose can be used. Minor therapeutic effect on its own > Used as adjunctive therapy with declining effects of L-dopa in later stages. 2.Rasagiline More potent than Selegiline

Question 35

what are the Catechol-O-methyl transferase (COMT) inhibitors

Answer 35

1. Entacapone and 2. Tolcapone Similar pharmacological effects Prolong the activity of L-dopa by preventing its peripheral breakdown > more L-dopa reaches the brain >Adjunct therapy to L-dopa in patients experience end of dose off symptoms

Question 36

what are the Antimuscarinic Drugs for PD and explain why they are used

Answer 36

1. Benzotropine; 2. Orphenadrine In striatum, normally, DA from substantia nigra has inhibitory effect whilst acetylcholine, from local interneurons has excitatory effect on striatal neurons In PD, the lack of DA and its inhibitory effect results in over excitation by cholinergic neurons Therefore, drugs which block muscarinic cholinergic receptors can be used to alleviate this imbalance. Not used in primary PD, only drug-induced PD

Question 37

what are the pharmacotherapy strategies for non motor symptoms. list each symptom with drug use to treatment them

Answer 37

Depression, psychosis > citalopram, quetiapine and clozapine dementia > Acetylcholinesterase Sleep disorders > clonazepam Restless legs syndrome Periodic limb movements of sleep REM sleep behaviour disorder falls Autonomic disturbance. > oxybutynin, tolterodine urinary dysfunction weight loss, dysphagia. constipation. > movicol erectile dysfunction orthostatic hypotension excessive sweating sialorrhoea

Question 38

List the non medical treatments

Answer 38

Brain Grafts and Stem Cell therapy Deep Brain Stimulation